Abstract Introduction Immune checkpoint inhibitors (ICIs) have become an important part of
the treatment of multiple cancers, especially for advanced melanoma and non-small cell …

This review aims to provide an understanding of the diagnostic and therapeutic challenges
of uveitis associated with immune checkpoint inhibitors (ICI). In the wake of these molecules …

Computational drug repositioning is an effective way to find new indications for existing
drugs, thus can accelerate drug development and reduce experimental costs. Recently …

Ocular immunotherapy-related adverse events (IRAEs), although rare, can be sight-
threatening. Our objective was to analyze ocular IRAEs diagnosed in France from the …

Background Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1)
inhibitors can cause unique immune-related adverse effects due to non-specific …

This study will provide a thorough review of systemic (and select intravitreal) medications,
along with illicit drugs that are capable of causing various patterns of retinal toxicity. The …

Ocular immune-related adverse events (IrAEs) associated with use of checkpoint inhibitors
(CPIs) in cancer therapeutics are relatively rare, occurring in approximately 1% of treated …

Treatments of numerous systemic and local diseases of different etiologies may be
accompanied by an unwanted side effect in the form of uveitis. We inform readers about …

Immune checkpoints are endogenous, inhibitory, receptor-mediated regulators of the
immune system known to be central to controlling the duration and extent of normal immune …

Objective: Rare disease Background: Immune checkpoint inhibitors (ICIs) targeting the
programmed cell death protein 1 (PD-1), or its ligand PD-L1, are the mainstay treatment for …